Key Highlights

  • Scholar Rock shares traded at $50.66, down 4.16% on the day.
  • The company completed its NDA submission to the FDA for SRK-181 in solid tumors.
  • Apitegromab in spinal muscular atrophy carries a PDUFA date of September 23, 2026.
  • Scholar Rock's market capitalization stands at approximately $6.07 billion.

Scholar Rock Holding Corporation (NASDAQ: SRRK) shares traded at $50.66, down 4.16% on the day, as the company continues to advance two late-stage programs: SRK-181 in solid tumors and apitegromab in spinal muscular atrophy.

What Happened

For SRK-181, part of the DRAGON program targeting solid tumors, the company has completed its New Drug Application (NDA) submission to the FDA. Phase 3 secondary endpoint data presented at ASRS showed that a biomarker measure remained stable or slightly decreased by 2% at month 25, compared with an approximate 20% increase in the placebo arm, noted July 20, 2026. This data follows previously reported topline results that met the primary endpoint, showing a statistically significant 35.7% reduction in retinal lesion growth rate compared with placebo.

For apitegromab, part of the SAPPHIRE program targeting Type 2 and Type 3 spinal muscular atrophy, the FDA has set a PDUFA date of September 23, 2026, after the company resubmitted its Biologics License Application (BLA) on March 31, 2026, following a Complete Response Letter (CRL) issued by the FDA on September 23, 2025.

Market Reaction

Shares traded down 4.16% at $50.66, with Scholar Rock's market capitalization at approximately $6.07 billion, according to the disclosed pipeline database.

The stock's decline comes even as the company reports continued progress on both of its late-stage programs, including a completed NDA submission and an upcoming PDUFA date.

Outlook

The apitegromab PDUFA date of September 23, 2026 represents a near-term regulatory catalyst following the BLA resubmission earlier this year.

The completed NDA submission for SRK-181 positions that program for FDA review, though the disclosed information does not include a specific PDUFA date for that submission.

What is the status of Scholar Rock's SRK-181 program?

The company has completed its NDA submission to the FDA for SRK-181 in solid tumors, following Phase 3 data showing a 35.7% reduction in retinal lesion growth rate versus placebo.

When is the PDUFA date for apitegromab?

The FDA has set a PDUFA date of September 23, 2026, following the company's BLA resubmission on March 31, 2026.

What indication is apitegromab being developed for?

Apitegromab is being developed for Type 2 and Type 3 spinal muscular atrophy under the SAPPHIRE program.